Signals, Powered By EquityPandit
Aurobindo Pharma has got the US health regulator’s approval for selling generic Zolmitriptan tablets, a drug that is used to treat migraine, in the American market.
Aurobindo Pharma has said in a regulatory filing that the company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Zolmitriptan Tablets in strengths of 2.5 mg and 5 mg.
It added that “this product is expected to be launched in second quarter of FY16-17.”
The company’s product is the generic equivalent of IPR Pharmaceuticals’ Zomig that is used in the treatment of migraine in adults.
